DelistingMay 29, 2026, 05:17 PM
Actinium Pharmaceuticals Receives NYSE American Delisting Notice
AI Summary
Actinium Pharmaceuticals, Inc. received a notice from NYSE American indicating non-compliance with continued listing standards. The company's stockholders' equity of approximately $2.3 million as of March 31, 2026, falls below the required $4.0 million, and it has reported net losses in its last five fiscal years. Actinium must submit a plan by June 26, 2026, to regain compliance by November 27, 2027, or face delisting proceedings. Separately, the company announced it will present new data on its ATNM-400 product candidate at the SNMMI 2026 Annual Meeting, showcasing its potential in prostate cancer and non-small cell lung cancer.
Key Highlights
- Actinium Pharmaceuticals received a notice from NYSE American on May 27, 2026, for non-compliance with listing standards.
- The company's stockholders' equity was approximately $2.3 million as of March 31, 2026, below the $4.0 million requirement.
- Actinium reported net losses in its last five fiscal years ended December 31, 2025.
- A compliance plan must be submitted by June 26, 2026, to regain compliance by November 27, 2027.
- The common stock will continue to trade on NYSE American under the symbol "ATNM" with a ".BC" indicator.
- The company will present new data on its ATNM-400 product candidate at the SNMMI 2026 Annual Meeting from May 30-June 2, 2026.
- ATNM-400 data will highlight efficacy in prostate cancer and non-small cell lung cancer models.
Price Impact
More from ATNM